Diseño y desarrollo de un sistema de mantenimiento predictivo y de estadísticas para plantas de celulosas y petroleras

77 p.La presente memoria revisa el diseño y desarrollo de un sistema web de mantenimiento predictivo para empresas relacionadas con el rubro de celulosas o petroleras. Este sistema surge como necesidad de agilizar y ayudar a la toma de decisiones tanto para gerentes como jefes de operaciones, dentro de las faenas y presentar de manera ordenada, limpia y consistente los resultados obtenidos en el trabajo de paradas generales de planta. Para el desarrollo de este sistema se realiz´o un estudio de las tecnolog´ıas existentes, dentro de las cuales se utilizaron dos poderosos lenguajes de programación y un motor de base de datos muy estable. Se utilizo también una metodología de desarrollo llamada Scrum, la cual fue adaptada para un optimo funcionamiento dentro de la organizaci´on. Dentro de los sistemas desarrollados se encuentran aplicaciones en ASP.NET y Rich Internet Applications (RIA), entregando una aplicaci´on atractiva para el usuario y muy simple de utilizar. Como últimos pasos se analizan problemas y sobresaltos ocurridos dentro del desarrollo del sistema, y son presentados los próximos pasos a seguir dentro del desarrollo y el resultado final obtenido./ABSTRACT: This thesis reviews the design and development of a predictive maintenance web system for cellulose or oil companies. This system arise as a need to improve and help the in decisions making process for managers and chief operations officer in a productive plant, and to present an organised, clean and consistent summary of the outcomes obtained during the general plant stops. To develop this system, a study of existing technologies was performed, among which two powerful programming languages and a very stable database engine were used. The development methodology called Srum was also used, which was adapted for optimal performance within the company. Among the developed systems, there are applications written in ASP.NET and Rich Internet Applications (RIA), which are attractive and very simple to use application for users. As final steps problems and difficulties arising during the system development are analised and future developments and final result are presented

Revista Temas Agrarios Volumen 26; Suplemento 1 de 2021

1st International and 2nd National Symposium of Agronomic Sciences: The rebirth of the scientific discussion space for the Colombian Agro.1 Simposio Intenacional y 2 Nacional de Ciencias Agronómicas: El renacer del espacio de discusión científica para el Agro colombiano

Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period

The objective of this work is to analyze the survival of infliximab, etanercept and adalimumab in patients who have switched among tumor necrosis factor (TNF) antagonists for the treatment of chronic arthritis. BIOBADASER is a national registry of patients with different forms of chronic arthritis who are treated with biologics. Using this registry, we have analyzed patient switching of TNF antagonists. The cumulative discontinuation rate was calculated using the actuarial method. The log-rank test was used to compare survival curves, and Cox regression models were used to assess independent factors associated with discontinuing medication. Between February 2000 and September 2004, 4,706 patients were registered in BIOBADASER, of whom 68% had rheumatoid arthritis, 11% ankylosing spondylitis, 10% psoriatic arthritis, and 11% other forms of chronic arthritis. One- and two-year drug survival rates of the TNF antagonist were 0.83 and 0.75, respectively. There were 488 patients treated with more than one TNF antagonist. In this situation, survival of the second TNF antagonist decreased to 0.68 and 0.60 at 1 and 2 years, respectively. Survival was better in patients replacing the first TNF antagonist because of adverse events (hazard ratio (HR) for discontinuation 0.55 (95% confidence interval (CI), 0.34-0.84)), and worse in patients older than 60 years (HR 1.10 (95% CI 0.97-2.49)) or who were treated with infliximab (HR 3.22 (95% CI 2.13-4.87)). In summary, in patients who require continuous therapy and have failed to respond to a TNF antagonist, replacement with a different TNF antagonist may be of use under certain situations. This issue will deserve continuous reassessment with the arrival of new medications. © 2006 Gomez-Reino and Loreto Carmona; licensee BioMed Central Ltd